Merck Inks Deal With Synthekine to Develop Novel Cytokine Therapeutics, Delays Deal to Acquire Acceleron

Merck has inked a deal worth more than $525 million with preclinical biotech Synthekine to develop and commercialize novel cytokine therapeutics that focus on autoimmune diseases.
Source: Drug Industry Daily